Get started
Cell Source, Inc.Cell Source, Inc.Cell Source, Inc.

Cell Source, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsDiscussionsTechnicalsSeasonals

CLCS fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Cell Source, Inc. is a biotechnology company, which focuses on developing cell therapy treatments based on the management of immune tolerance. Its Veto Cell immune system management technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. The Veto Cell platform roadmap consists of two main programs: VETO CAR-T (with and without HSCT) and Veto Cell Organ Transplantation. The company was founded on June 6, 2012 and is headquartered in New York, NY.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
CLCS has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company